iZafe Group’s CEO Anders Segerström Acquires an Additional 208,333 Shares

STOCKHOLM, SWEDEN / ACCESSWIRE / August 28, 2023 / iZafe Group (STO:IZAFE-B.ST) iZafe Group’s CEO, Anders Segerström, has today acquired an additional 208,333 B-shares in the company. The transaction was completed at a total value of 50,000 SEK, equivalent to 0.24 SEK per share. With this latest purchase, Anders Segerström now holds a total of 1,598,773 B-shares in iZafe Group.

“It is with pleasure and belief that I increase my ownership stake in iZafe Group. This decision reflects my full confidence in our dedicated team and our future potential. Today, we stand on a strong foundation to collectively continue working hard towards creating a successful future for our shareholders, the company, individuals who require multiple medications, society, and healthcare.” says Anders Segerström, CEO iZafe Group AB.

Contacts

Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm
E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution and the connected dose bag Pilloxa. The company’s solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company’s Certified Adviser. Further information is available at www.izafegroup.com

Image Attachments

Anders Segerstrom

Attachments

iZafe Group’s CEO Anders Segerström acquires an additional 208,333 shares.

SOURCE: iZafe Group

View source version on accesswire.com:
https://www.accesswire.com/777581/iZafe-Groups-CEO-Anders-Segerstrm-Acquires-an-Additional-208333-Shares

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

2 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

2 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

1 day ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

1 day ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

1 day ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

1 day ago